What is holding Industry back from Implementing Continuous Processing: Can Asia Adopt More Quickly?
Posted on December 15, 2015
By: Morten Munk, Senior Technology Partner
Global Business Development, NNE Pharmaplan, Gentofte, Denmark
Eric Langer, Managing Partner
BioPlan Associates, Inc. Rockville, MD USA
Biopharma Not Quite Ready to Say Goodbye to Batches Although few biologics today are made using continuous bioprocessing (CBP) equipment like bioreactors—that may be changing. And Asian bioprocessing facilities may have an opportunity to take a more leading role. While it is difficult to displace ...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
batch processing, Batches, CBP, Continuous Bioprocessing, Continuous Manufacturing, Continuous Processing, Continuous upstream bioprocessing, Eric S. Langer, Morten Munk, NNE Pharmaplan, single-use, upstream technologies
Related Product Videos
Security of supply your concern, our mission - GE Healthcare Life Sciences
Related Products
Security of supply - Your concern, our mission - GE Healthcare Life SciencesSubscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
